Literature DB >> 29737505

Drug-Eluting Stents for Treatment of Peripheral Artery Disease.

Kazeen Abdullah1, Bassel Bou Dargham1, Micah Steinbrecher1,2, Bo Sun1, Zhao Huiqiang3, Houman Khalili1,2, Emmanouil S Brilakis1,4, Subhash Banerjee5,6.   

Abstract

Endovascular intervention is a mainstay treatment of peripheral artery disease (PAD) in addition to aggressive risk factor modification and exercise programs in patients with favorable anatomy or in those who are considered too high risk for surgical intervention. Treatment with percutaneous transluminal angioplasty (PTA) and bare metal stents (BMS) has been limited by high rates of in-stent restenosis (ISR) requiring repeat revascularization. Drug-eluting stents (DES), developed and designed to reduce ISR, offer a promising solution to the current challenges in endovascular management of PAD. Several randomized clinical trials have shown improved short- and mid-term outcomes with DES as compared with both PTA and BMS. Herein we provide an up-to-date review of the current literature on DES use in PAD.

Entities:  

Mesh:

Year:  2018        PMID: 29737505     DOI: 10.1007/s40256-018-0265-4

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  2 in total

1.  A homogenized constrained mixture model of restenosis and vascular remodelling after balloon angioplasty.

Authors:  Lauranne Maes; An-Sofie Cloet; Inge Fourneau; Nele Famaey
Journal:  J R Soc Interface       Date:  2021-05-05       Impact factor: 4.118

2.  A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective.

Authors:  Nishath Altaf; Thathya Venu Ariyaratne; Adrian Peacock; Irene Deltetto; Jad El-Hoss; Shannon Thomas; Colman Taylor; Bibombe Patrice Mwipatayi
Journal:  Cardiovasc Intervent Radiol       Date:  2021-06-21       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.